** Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket
** Brokerage H.C. Wainwright starts coverage with "buy" rating, sets PT at $36
** The new price target is more than double the stock's last close
** Brokerage says a late-stage study of "underappreciated" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025
** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes
** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study
** Up to last close, stock up 14.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。